Comparable stake leader
PERCEPTIVE ADVISORS LLC
SEC ownership of enGene Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001980845.
Disclosed value leader
Fonds de solidarite des travailleurs et des travailleuses du Quebec
Comparable rows
50/50
Latest evidence
20 Jul 2026
- Public ticker
- ENGN, ENGNW on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PERCEPTIVE ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PERCEPTIVE ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001980845
- Issuer location
- Saint Laurent
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of enGene Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
Fonds de solidarite des t...
Comparable rows
50/50
Latest evidence
20 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: PERCEPTIVE ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
PERCEPTIVE ADVISORS LLC
10%
BML Investment Partners, L.P.
10%
Invus Global Management, LLC
9.3%
ACORN BIOVENTURES, L.P.
5%
Fonds de solidarite des travaille...
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
10%
|
$11,936,659
6,899,803 shares
|
+$223,513 | 30 Jun 2026 |
| BML Investment Partners, L.P. |
13D/G
|
10%
|
$45,088,578
6,669,908 shares
|
+$9,767,578 | 12 May 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
9.3%
|
$12,012,791
6,256,662 shares
|
$0 | 30 Jun 2026 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
5%
|
$22,695,226
3,357,282 shares
|
$0 | 20 Jul 2026 |
| Fonds de solidarite des travailleurs et des travailleuses du Quebec |
3/4/5
13D/G
10%+ Owner
|
4.5%
from 13D/G
|
$45,542,295
3,036,153 shares
|
— | 18 Apr 2024 |
| Adage Capital Management, L.P. |
13D/G
|
3%
|
$6,115,072
1,528,768 shares
|
$0 | 31 Dec 2024 |
| Kynam Capital Management, LP |
13D/G
13F
Company
|
2.2%
|
$12,510,485
1,492,898 shares
|
-$29,339,989 | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
1.8%
|
$3,781,608
945,402 shares
|
-$8,424,148 | 27 Jan 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$10,051.
Buys
$10,051
Insiders: 1
Sells
$0
Insiders: 0
Net
+$10,051
Shares: +5,102
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 5,102
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 5,102 | 0 | $10,051 | $0 | +$10,051 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 32 reporting-owner rows connected to enGene Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
32
Largest Forms 3/4/5 holder
Forbion Growth Opportunities Fund I Cooperatief U.A.
Net 12M change
+$10,051
Latest report
22 Sep 2026
Recent insider transactions for enGene Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| William Grossman | ENGN | Common Shares | Purchase | $10,051 | $1.97 | 5,102 | 5,102 | 22 Sep 2026 | Direct | |
| Philip Astley-Sparke | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Gerald A. Brunk | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Richard M. Glickman | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| William Grossman | ENGN | Stock Option (Right to Buy) | Award | 231,000 | 200,000 | 16 Jun 2026 | Direct | |||
| Paul J. Hastings | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Michael Thomas Heffernan | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Wouter Joustra | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Lota S. Zoth | ENGN | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 16 Jun 2026 | Direct | |||
| Anthony T. Cheung | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Alexander J. Nichols | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Joan Connolly | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Matthew Ross Boyd | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Lee Giguere | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Jill Buck | ENGN | Stock Option (Right to Buy) | Award | 195,000 | 195,000 | 30 Jan 2026 | Direct | |||
| Ronald Harold Wilfred Cooper | ENGN | Stock Option (Right to Buy) | Award | 801,000 | 801,000 | 30 Jan 2026 | Direct | |||
| D. Ryan Daws | ENGN | Stock Option (Right to Buy) | Award | 220,000 | 220,000 | 30 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.